Dianthus Therapeutics (NASDAQ:DNTH) Issues Earnings Results

Dianthus Therapeutics (NASDAQ:DNTH) released its quarterly earnings data on Tuesday. The company reported ($0.81) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.85) by $0.04, Zacks reports. Dianthus Therapeutics had a negative net margin of 1,250.32% and a negative return on equity of 21.68%. The company had revenue of $1.33 million during the quarter, compared to analysts’ expectations of $1.40 million.

Dianthus Therapeutics Price Performance

Shares of DNTH stock opened at $21.90 on Thursday. The firm’s 50-day moving average is $22.65 and its two-hundred day moving average is $24.94. Dianthus Therapeutics has a 12 month low of $18.13 and a 12 month high of $33.77. The company has a market capitalization of $648.17 million, a PE ratio of -8.76 and a beta of 1.82.

Analyst Ratings Changes

A number of research firms have weighed in on DNTH. Raymond James raised shares of Dianthus Therapeutics to a “moderate buy” rating in a report on Thursday, December 12th. HC Wainwright reiterated a “buy” rating and issued a $40.00 target price on shares of Dianthus Therapeutics in a research report on Wednesday. Wedbush reiterated an “outperform” rating and issued a $36.00 target price on shares of Dianthus Therapeutics in a research report on Wednesday. Guggenheim reiterated a “buy” rating and issued a $84.00 target price on shares of Dianthus Therapeutics in a research report on Wednesday. Finally, TD Cowen assumed coverage on shares of Dianthus Therapeutics in a research report on Friday, December 20th. They issued a “buy” rating on the stock. Eight equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Buy” and a consensus price target of $52.14.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.